Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients
- 25 November 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Hypertension Research
- Vol. 34 (1), 145-151
- https://doi.org/10.1038/hr.2010.205
Abstract
We planned a randomized, double blind clinical trial to evaluate whether an antihypertensive intervention at the proximal or distal level of the renin–angiotensin–aldosterone system could have different effects on a broad range of innovative cardiovascular risk biomarkers. A total of 288 hypertensive Caucasian patients (115 men and 113 women), aged ⩾18 years, were enrolled in this study. They were randomized to take losartan 50 mg per day or ramipril 5 mg per day for 1 month and titrated up to 100 mg per day and 10 mg per day for 13 months, respectively. At baseline, 1, 2 and 14 months after therapy initiation, we evaluated the following parameters: body weight, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), M-value, adiponectin (ADN), resistin (r), retinol binding protein-4 (RBP-4), visfatin, vaspin, high-sensitivity C-reactive protein (Hs-CRP), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). No variation of body weight, BMI, FPG or vaspin was obtained with either treatment. We recorded a similar improvement in SBP, DBP and Hs-CRP with both treatments; however, losartan also increased M-value, ADN and visfatin, whereas ramipril did not. Furthermore, losartan decreased r, RBP-4, MMP-2 and MMP-9, whereas ramipril did not have any effect on these parameters. In conclusion, we observed that short-term treatment with losartan improved several metabolic parameters (M-value, ADN, RBP-4, r and visfatin) and decreased vascular remodeling biomarkers (MMP-2 and MMP-9) in hypertensive subjects, whereas ramipril did not.Keywords
This publication has 43 references indexed in Scilit:
- Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current statusBritish Journal of Pharmacology, 2010
- Chronic Treatment With Losartan Results in Sufficient Serum Levels of the Metabolite EXP3179 for PPARγ ActivationHypertension, 2009
- Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartanNephrology Dialysis Transplantation, 2009
- Angiotensin AT2 receptors: control of renal sodium excretion and blood pressureTrends in Endocrinology & Metabolism, 2008
- Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjectsDiabetes & Metabolism, 2007
- Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?Current Opinion in Pharmacology, 2007
- Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndromeNephrology, 2007
- The CNS renin-angiotensin systemCell and tissue research, 2006
- Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension.: Relationship to left ventricular mass and anti-hypertensive therapyInternational Journal of Cardiology, 2000
- Insulin Resistance in Essential HypertensionNew England Journal of Medicine, 1987